NR3C2 and chronic kidney disease: With increasing use of emerging medical therapies such as non-steroidal mineralocorticoid receptor antagonists to delay CKD progression [42,43], it remains common practice to advise patients to restrict dietary potassium, either with or without the use of novel potassium binding resins, in order to optimize the prescription of RAAS inhibitors [44,45,46].